{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urticaria+Chronic&page=4", "query": { "condition": "Urticaria Chronic", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 96, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urticaria+Chronic&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urticaria+Chronic&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T08:16:02.271Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04538794", "title": "A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "CDX-0159", "type": "DRUG" }, { "name": "Normal Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 45, "start_date": "2020-09-24", "completion_date": "2023-01-17", "has_results": false, "last_update_posted_date": "2023-07-19", "last_synced_at": "2026-10-09T08:16:02.271Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Sarasota, Florida + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boise", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT04538794" }, { "nct_id": "NCT04976192", "title": "Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Urticaria" ], "interventions": [ { "name": "TEV-45779", "type": "COMBINATION_PRODUCT" }, { "name": "XOLAIR® Injection", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Teva Pharmaceuticals USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 608, "start_date": "2021-08-30", "completion_date": "2024-04-05", "has_results": true, "last_update_posted_date": "2025-10-07", "last_synced_at": "2026-10-09T08:16:02.271Z", "location_count": 9, "location_summary": "Bakersfield, California • Clearwater, Florida • Coral Gables, Florida + 6 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Kissimmee", "state": "Florida" }, { "city": "Maitland", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04976192" }, { "nct_id": "NCT00619801", "title": "Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Allergic Rhinitis", "Chronic Urticaria" ], "interventions": [ { "name": "Levocetirizine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "6 Years", "sex": "ALL", "summary": "2 Years to 6 Years" }, "enrollment_count": 173, "start_date": "2008-03", "completion_date": "2008-07", "has_results": true, "last_update_posted_date": "2015-03-06", "last_synced_at": "2026-10-09T08:16:02.271Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Crescent City", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00619801" }, { "nct_id": "NCT03580369", "title": "A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "Ligelizumab", "type": "BIOLOGICAL" }, { "name": "Omalizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1072, "start_date": "2018-10-17", "completion_date": "2022-06-14", "has_results": true, "last_update_posted_date": "2023-07-24", "last_synced_at": "2026-10-09T08:16:02.271Z", "location_count": 30, "location_summary": "Gilbert, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 26 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Litchfield Park", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03580369" }, { "nct_id": "NCT06077773", "title": "Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "Oral EP262", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Escient Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 113, "start_date": "2023-09-25", "completion_date": "2025-01-16", "has_results": true, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-10-09T08:16:02.271Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06077773" }, { "nct_id": "NCT04681729", "title": "Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cold Urticaria" ], "interventions": [ { "name": "Dupilumab SAR231893", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Non sedating H1-antihistamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "12 Years to 80 Years" }, "enrollment_count": 82, "start_date": "2020-12-10", "completion_date": "2023-04-20", "has_results": true, "last_update_posted_date": "2025-09-10", "last_synced_at": "2026-10-09T08:16:02.271Z", "location_count": 5, "location_summary": "San Diego, California • Boise, Idaho • Owensboro, Kentucky + 2 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Boise", "state": "Idaho" }, { "city": "Owensboro", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04681729" }, { "nct_id": "NCT00685373", "title": "Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cryopyrin-Associated Periodic Syndromes", "Familial Cold Autoinflammatory Syndrome", "Muckle Wells Syndrome", "Neonatal Onset Multisystem Inflammatory Disease" ], "interventions": [ { "name": "Canakinumab (ACZ885)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 166, "start_date": "2008-05", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2016-11-04", "last_synced_at": "2026-10-09T08:16:02.271Z", "location_count": 6, "location_summary": "Little Rock, Arkansas • San Francisco, California • Columbus, Georgia + 3 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00685373" }, { "nct_id": "NCT00887939", "title": "Pathogenesis of Physical Induced Urticarial Syndromes", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hypersensitivity, Immediate", "Autoinflammatory Syndromes", "Physical Urticaria", "Familial Cold Autoinflammatory Syndrome" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "2 Years to 90 Years" }, "enrollment_count": 173, "start_date": "2009-06-17", "completion_date": "2024-06-03", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-10-09T08:16:02.271Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00887939" }, { "nct_id": "NCT04612725", "title": "A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "Benralizumab", "type": "BIOLOGICAL" }, { "name": "Placebo and Benralizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 159, "start_date": "2020-10-27", "completion_date": "2023-03-28", "has_results": true, "last_update_posted_date": "2024-03-13", "last_synced_at": "2026-10-09T08:16:02.271Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Mission Viejo, California + 8 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04612725" }, { "nct_id": "NCT06050928", "title": "Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Inducible Urticaria" ], "interventions": [ { "name": "Oral EP262", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Escient Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 33, "start_date": "2023-08-30", "completion_date": "2024-10-22", "has_results": false, "last_update_posted_date": "2024-12-09", "last_synced_at": "2026-10-09T08:16:02.271Z", "location_count": 7, "location_summary": "Tampa, Florida • Boise, Idaho • Owensboro, Kentucky + 4 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Boise", "state": "Idaho" }, { "city": "Owensboro", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06050928" } ] }